<?xml version="1.0" encoding="UTF-8"?>
<GaPExchange xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="./dbGaPEx2.1.5.xsd">

<MetaVariables>
	<Submitter/>
	<Method/>
</MetaVariables>
<MetaLinks/>

<Projects>
	<Project/>
</Projects>

<Studies>

<Study source="dbGaP" accession="phs000994.v1.p1" parentStudy="phs000994.v1.p1" createDate="2015-09-24" modDate="2015-09-24">

<Configuration>
	<Data_Provider><![CDATA[
		<table border="1">
		<tr><th>Title</th><th>Name</th><th>Institute</th></tr>
		<tr><td>Principal Investigator</td><td>Teresa Palomero</td><td>Columbia University, New York, NY, USA</td></tr>
		<tr><td>Funding Source</td><td>TRP award</td><td>Leukemia and Lymphoma Society</td></tr>
		</table>
	]]></Data_Provider>
	<StudyNameEntrez>The Mutational Landscape of CTCL and Sezary Syndrome.</StudyNameEntrez>
	<StudyNameReportPage>The Mutational Landscape of CTCL and Sezary Syndrome</StudyNameReportPage>
	<StudyTypes>
		<StudyType>Longitudinal Cohort</StudyType>
		<StudyType>Tumor vs. Matched-Normal</StudyType>
	</StudyTypes>
	<Description><![CDATA[
<p>Sezary syndrome is a leukemic and aggressive form of cutaneous T-cell lymphoma (CTCL) resulting from the malignant transformation of skin-homing central memory CD4+ T cells. To identify new genetic alterations involved in Sezary syndrome and CTCL transformation we performed whole-exome sequencing of tumor-normal sample pairs from 26 Sezary syndrome and 16 CTCL patients. These analyses revealed a distinctive pattern of somatic copy number alterations in Sezary syndrome including highly prevalent recurrent chromosomal deletions involving the TP53, RB1, PTEN, DNMT3A, and CDKN1B tumor suppressor genes. Mutation analysis identified a broad spectrum of somatic mutations involving key genes involved in epigenetic regulation (TET2, CREBBP, MLL3, BRD9, SMARCA4 and CHD3) and signaling, including mutations in MAPK1, BRAF, CARD11 and PRKG1 driving increased MAPK, NFKB and NFAT activity upon T-cell receptor stimulation. Collectively, our findings provide new insights into the genetics of Sezary syndrome and CTCL and support the development of personalized therapies targeting key oncogenically activated signaling pathways for the treatment of these diseases.</p>]]>
	</Description>
	<StudyProjects>
		<Project/>
	</StudyProjects>
	<Publications>
		<Publication>
			<Journal authors="Ana Carolina da Silva Almeida, Francesco Abate, Hossein Khiabanian, Estela Martinez-Escala, Joan Guitart, Cornelis P. Tensen, 			Maarten H. Vermeer, Raul Rabadan, Adolfo Ferrando, Teresa Palomero" title="The mutational landscape of CTCL and Sezary syndrome" journal="Nature Genetics, in press"/>
		</Publication>
	</Publications>
	<Diseases>
		<Disease vocab_source="MESH" vocab_term="Sezary Syndrome"/>
		<Disease vocab_source="MESH" vocab_term="Mycosis Fungoides"/>
	</Diseases>
	<Attributions>
		<Header title="Principal Investigator">
			<AttName>Teresa Palomero</AttName>
			<Institution>Columbia University, New York, NY, USA</Institution>
		</Header>
		<Header title="Funding Source">
			<AttName>TRP award</AttName>
			<Institution>Leukemia and Lymphoma Society</Institution>
		</Header>
	</Attributions>
	<DisplayPublicSummary>yes</DisplayPublicSummary>
	<ConsentGroups>
		<ConsentGroup groupNum="1" shortName="DS-CA-IRB-PUB" longName="Disease-Specific (Cancer, IRB, PUB)"/>
	</ConsentGroups>
</Configuration>

  <AuthorizedAccess>
    <DacInfo ssDacId="0">
      <DacName>NCI</DacName>
      <DacFullName>NCI</DacFullName>
      <DacEmail>0</DacEmail>
      <DacPhone></DacPhone>
      <DacUrl></DacUrl>
    </DacInfo>
    <Policy Policy_ID="phs000994.v1.p1_policy" ref_ssDacId="0">
      <DisplayResearchStatement>yes</DisplayResearchStatement>
      <DisplayPublicSummary>yes</DisplayPublicSummary>
      <EmbargoLength>0</EmbargoLength>
      <YearsUntilRenewal>1</YearsUntilRenewal>
      <WeeksCancelRequest>8</WeeksCancelRequest>
      <PdfSupplementReqired>yes</PdfSupplementReqired>
      <AcknowledgementText>
        <para>
          http://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000994.v1.p1
        </para>
      </AcknowledgementText>
      <DocumentSet>
        <DataUseCertificate Label="Data Use Certificate" FilePath="https://dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=DUC&amp;view_pdf&amp;stacc=phs000994.v1.p1" FileName=""/>
      </DocumentSet>
    </Policy>
    <ConsentGroups>
      <ParticipantSet groupNum-REF="1">
        <ConsentName>Disease-Specific (Cancer, IRB, PUB)</ConsentName>
        <ConsentAbbrev>DS-CA-IRB-PUB</ConsentAbbrev>
        <UseLimitation>Use of the data must be related to Cancer.
Requestor must provide documentation of local IRB approval.
Requestor agrees to make results of studies using the data available to the larger scientific community.</UseLimitation>
        <IrbRequired>Yes</IrbRequired>
      </ParticipantSet>
    </ConsentGroups>
  </AuthorizedAccess>


</Study>

</Studies>

</GaPExchange>
